Economic Modeling of Neuromuscular Blockade in ARDS Patients
Author Information
Author(s): Macario Alex, Chow John L, Dexter Franklin
Primary Institution: Stanford University School of Medicine
Hypothesis
Would a reduction in intubation time of 6 hours and/or a reduction in the incidence of AQMS from 25% to 21% provide enough benefit to justify an additional expenditure of $267?
Conclusion
ARDS patients receiving a neuromuscular blocker have a high mortality and unpredictable outcomes, leading to large variability in costs per case.
Supporting Evidence
- The mean cost for ARDS patients receiving standard care for 6 months was predicted to be $62,238.
- 39% of hypothetical patients with ARDS would be expected to be dead after 6 months.
- The net monetary benefit of reducing both AQMS and ventilation time would be positive for only 51% of patients.
Takeaway
This study used a computer model to see if using a certain drug for ARDS patients is worth the extra money, but found that it might not help much.
Methodology
A Markov model was designed with hypothetical patients in 1 of 6 mutually exclusive health states over a period of 6 months.
Limitations
A prospective, randomized pharmacoeconomic study of neuromuscular blockers in the ICU is impractical due to the highly variable clinical course of patients with ARDS.
Participant Demographics
Base case was a 55 year-old man in the ICU with ARDS.
Statistical Information
Confidence Interval
$42,259 – $83,766
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website